Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | CPA2 | P48052 | 1/20 | 0.39 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10136486 | 1.00 | P2RX7 (0.45) | P2RX7F2KDM4ESMN1; SMN2PDK2 | |
| SCHEMBL12258952 | 1.00 | P2RX7 (0.45) | P2RX7F2KDM4ESMN1; SMN2PDK2 | |
| SCHEMBL22040436 | 0.94 | MAPK10 (0.43) | P2RX7F2KDM4ESMN1; SMN2MAPK10 | |
| SCHEMBL16530314 | 0.85 | KDM4E (0.44) | F2KDM4ESMN1; SMN2PDK2POLB | |
| SCHEMBL21075247 | 0.85 | P2RX7 (0.45) | P2RX7F2KDM4ESMN1; SMN2TNKS | |
| SCHEMBL22980126 | 0.85 | KDM4E (0.44) | F2KDM4ESMN1; SMN2PDK2POLB | |
| SCHEMBL4555085 | 0.85 | KDM4E (0.44) | F2KDM4ESMN1; SMN2PDK2POLB | |
| SCHEMBL13554426 | 0.83 | KDM4E (0.42) | KDM4ESMN1; SMN2PDK2POLBNPSR1 | |
| SCHEMBL16104095 | 0.83 | KDM4E (0.42) | KDM4ESMN1; SMN2PDK2POLBNPSR1 | |
| SCHEMBL17069029 | 0.83 | F2 (0.47) | P2RX7F2KDM4ESMN1; SMN2TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146892-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-9687562-B2 | Polymers having therapeutically active agents conjugated thereto, processes of preparing same and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-06-27 | — | — | US | disclosed |
| EP-3147279-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | Fuji Chemical Industry Co., Ltd. (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20160108400-A1 | Single-Stranded Nucleic Acid Molecule for Controlling Gene Expression | BONAC CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-9206422-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9200278-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20150011605-A1 | Single-Stranded Nucleic Acid Molecule for Controlling Gene Expression | BONAC CORPORATION (JP) | 2015-01-08 | — | — | US | disclosed |
| US-8785121-B2 | Single-stranded nucleic acid molecule for controlling gene expression | BONAC CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140171633-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | BONAC CORPORATION (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20140171486-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | BONAC CORPORATION (JP) | 2014-06-19 | — | — | US | disclosed |
| US-8691782-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | IHI CORPORATION (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | BONAC CORPORATION (JP) | 2012-02-09 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | P2RX7 947/4885F2 2851/4885KDM4E 3844/4885 |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | SSBP1, KCNN1, IMMT | P2RX7 4299/4885F2 1948/4885KDM4E 3391/4885 |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | CYP4B1, CYP2B6, UGT2B7 | P2RX7 590/4885F2 1774/4885KDM4E 872/4885 |
| US-20140171633-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | NSUN2, CTDSP1, RNGTT | P2RX7 3856/4885F2 4836/4885KDM4E 1652/4885 |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | NSUN2, CTDSP1, RNGTT | P2RX7 3856/4885F2 4836/4885KDM4E 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.